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The  anti-depressant  ﬂuoxetine  is widely  present  in  the  aquatic  environment.  Typical  river concentrations
are  in  the  low  ng/L range.  Many  ecotoxicity  studies  have  assessed  the  effects  of  this  pharmaceutical  on a
range of  aquatic  species.  Some  studies  report  that  ng,  or even  pg, per  litre  concentrations  cause  effects,




It  seems  unlikely  that  all reported  effects  will  be repeatable.  Many  of the  studies  have  considerable
limitations.  Currently  it is impossible  to ascertain  what  environmental  concentrations  of ﬂuoxetine  pose
a risk  to aquatic  organisms.  The  key question  can  be answered  only by high  quality,  reproducible  research.nvertebrates
ariable potency
. Introduction
Fluoxetine (also known by a number of trade names includ-
ng Prozac) is an antidepressant and one member of a class of
rugs known as selective serotonin reuptake inhibitors (SSRI). It
as been used for over 25 years to treat major depression and
ther psychiatric disorders. Its widespread use in many countries
ccounts for its presence in the aquatic environment. Fluoxetine
s present in rivers at concentrations in the low to very low ng/L
ange. An extremely comprehensive report by Gardner et al. (2012)
rovides information on ﬂuoxetine concentrations in the efﬂu-
nts of 162 wastewater treatment works in the United Kingdom.
he median concentration was 23 ng/L and the 95 percentile was
9 ng/L. Hydrological modelling can then be used to predict river
oncentrations. Predicted ﬂuoxetine concentrations in most loca-
ions and under most circumstances would be expected to be a few
g/L, but in highly impacted rivers under low ﬂow conditions could
each tens of ng/L. The relatively few measured river concentra-
ions of ﬂuoxetine in Europe support the predicted concentrations
Alonso et al., 2010; Vystavna et al., 2012). Hence, a legitimate ques-
ion to ask is whether or not aquatic organisms are affected by
uch concentrations. This question was ﬁrst addressed seriously ten
ears ago (Brooks et al., 2003), in a wide range of aquatic species,
 This is an open-access article distributed under the terms of the Creative Com-
ons Attribution-NonCommercial-No Derivative Works License, which permits
on-commercial use, distribution, and reproduction in any medium, provided the
riginal author and source are credited.
∗ Corresponding author. Tel.: +44 1895 266 303; fax: +44 1895 269 761.
E-mail address: john.sumpter@brunel.ac.uk (J.P. Sumpter).
166-445X/$ – see front matter © 2014 The Authors. Published by Elsevier B.V. All rights 
ttp://dx.doi.org/10.1016/j.aquatox.2013.12.010©  2014  The  Authors.  Published  by  Elsevier  B.V.  All rights  reserved.
but without utilising any speciﬁc mode-of-action endpoints. Since
then, approximately 30 studies on the effects of ﬂuoxetine on ﬁsh
have been published, together with about a dozen studies covering
effects of ﬂuoxetine on various species of invertebrates. Thus, in
the last ten years a reasonable amount of information has accumu-
lated that ought to enable us to reach a robust conclusion regarding
the possible threat that ﬂuoxetine poses to aquatic species. How-
ever, the current body of information does not enable any such
conclusion to be reached; the reasons for that are discussed below.
1.1. Effects of ﬂuoxetine on ﬁsh
Most of the 30 papers that have reported on the effects of ﬂuox-
etine on ﬁsh have studied the effect of the drug on the behaviour
of the ﬁsh. This seems a very sensible endpoint to concentrate on,
because the drug affects behaviour in humans, and hence based
on the read-across hypothesis (Hugget et al., 2003; Rand-Weaver
et al., 2013), effects on behaviour are likely to be the primary effect
of the drug on ﬁsh. Although there are many differences in the
studies that have reported on the behavioural effects of ﬂuoxetine
on ﬁsh – such as differences in exposure scenario, concentration,
duration, species, and age of ﬁsh as well as methodology to quan-
tify behaviour – it might have been expected that the effective
concentration of the drug would have been approximately the
same in all the studies, but this is not the case. The majority of
studies report that concentrations between 30 and 100 g ﬂuoxe-
tine/L affected behaviour (e.g. Pittman and Ichikawa, 2013; Wong
et al., 2013), as did higher concentrations (e.g. Kohlert et al., 2012;
Airhart et al., 2007). However, some studies report that very much
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arry (2013) reported that 0.3 g ﬂuoxetine/L affected swimming
peed, schooling behaviour and response to a predator alarm, and
zieweczynski and Hebert (2012) reported that 0.54 g ﬂuoxe-
ine/L reduced aggression of male Siamese ﬁghting ﬁsh.
Although possible effects on behaviour have understandably
een the main focus of studies investigating the effects of ﬂuox-
tine on ﬁsh, possible effects on other physiological processes have
een investigated. A number of studies have utilised various repro-
uctive endpoints. For example, Schultz et al. (2011) reported that
8 ng ﬂuoxetine/L had reproductive effects on male fathead min-
ows: the plasma vitellogenin concentration was increased, and
he architecture of their testes affected. Mennigen et al. (2010a)
tudied the effects of ﬂuoxetine on a wide range of reproductive
arameters of the goldﬁsh, and found that many of them were
ffected by both 0.54 and 54 g ﬂuoxetine/L, with the higher con-
entration generally producing the larger effects. The same group
f authors (Mennigen et al., 2010b) also reported that both these
oncentrations also disrupted feeding and energy metabolism in
oldﬁsh.
In summary, although many authors report effects of ﬂuoxetine
n ﬁsh occurring when the concentration in the water is in the tens
o hundreds of gs/L, some authors report signiﬁcant effects when
he water concentration is in the ng/L range.
.2. Effects of ﬂuoxetine on invertebrates
It is not only vertebrates that utilise serotonin as a neurotrans-
itter: invertebrates do as well. Therefore, following the concept
f read-across (Rand-Weaver et al., 2013), which states that as long
s the target is present, pharmaceuticals will have the same mode-
f-action in all species (see later for a more detailed description
f this hypothesis), it is possible that ﬂuoxetine could also have
peciﬁc mode-of-action effects on a variety of different species of
nvertebrates. The concentrations of ﬂuoxetine reported to cause
ffects are highly variable, covering as they do a range of more than
ne million-fold. Currently the lowest effective concentration is
.3 ng/L; this concentration was reported to cause a number of bio-
hemical and molecular effects on a species of mussel (Franzellitti
t al., 2013). Concentrations in the ng/L range have also been
eported to adversely affect learning and memory retention in a
uttleﬁsh (Di Poi et al., 2013), to trigger gamete release from mus-
els (Lazzara et al., 2012), and to affect swimming behaviour of an
mphipod (Guler and Ford, 2010). In contrast, the lowest concen-
ration of ﬂuoxetine required to induce spawning and parturition
n other species of bivalves was 30.9 g/L (Fong and Molnar, 2008),
nd Bringolf et al. (2010) found that only the two highest concen-
rations they tested, namely 300 and 3000 g/L, had reproductive
ffects on various species of freshwater mussels.
In summary, much of the published data can be interpreted as
eaning that, in general, invertebrates are more sensitive to ﬂuoxe-
ine than ﬁsh are. However, different species appear to demonstrate
ery different sensitivities, making it impossible to reach any gen-
ral conclusions.
.3. Limitations of the published studies
Perhaps understandably, the ﬁrst studies in any new ﬁeld – here
Pharmaceuticals in the environment’, or PIE – have limitations,
ecause there is little, if any, existing information on which to build.
ost of the currently published studies on the possible effects of
uoxetine on aquatic organisms suffer from one or more limita-
ions, the most important of which are brieﬂy discussed below:a) Lack of a concentration–response relationship.
Although many scientists appear to believe in ‘low-dose’
effects, meaning that low doses (or concentrations) can cause
effects that higher doses/concentrations do not (Vanderbergcology 151 (2014) 57–60
et al., 2012), we  believe that most ‘low dose’ effects are arte-
facts, and are unlikely to be repeatable. Many studies of the
possible effects of ﬂuoxetine on aquatic organisms involved the
use of only one concentration of the drug (e.g. Dzieweczynski
and Hebert, 2012; Egan et al., 2009; Franzellitti et al., 2013), or
at most two  (Wong et al., 2013; Kohlert et al., 2012; Mennigen
et al., 2010; Di Poi et al., 2013), making it very difﬁcult, if not
impossible, to determine if any effects were concentration-
related. When a wide range of concentrations has been used, it
has usually been reported that only the highest concentration(s)
causes signiﬁcant effects (e.g. Winder et al., 2012; Bringolf et al.,
2010; Fong and Molnar, 2013). However, sometimes a sig-
moidal dose–response relationship has not been found when
a wide range of concentrations have been tested, and instead
a non-monotonic relationship has been reported, where low
concentrations appeared to cause effects that higher concen-
trations did not (e.g. Guler and Ford, 2010). In such cases, it is
unknown whether or not the results are repeatable (see below).
b) No replication.
As far as we  can judge, very few of the studies reporting appar-
ent effects of ﬂuoxetine on aquatic organisms have involved
more than one experiment. If practical, scientists should always
assess the repeatability of their results before publishing them.
This is especially true if the results are surprising, or even
startling, and likely to elicit interest and possibly also consid-
erable concern. Hence, results suggesting that concentrations
of ﬂuoxetine in the ng/L range, which are therefore similar to
environmental concentrations, cause adverse effects to aquatic
organisms need to be demonstrated to be repeatable. Currently
it is unclear if the apparent effects of ng or even sub-ng/L con-
centrations of ﬂuoxetine in, for example, ﬁsh behaviour (Barry,
2013), reproduction and metabolism of ﬁsh (Mennigen et al.,
2010a,b), behaviour of cuttleﬁsh (Di Poi et al., 2013), and vari-
ous processes in mussels (Franzellitti et al., 2013; Lazzara et al.,
2012) will be reproducible, because in all cases the results
of only a single experiment were reported. However, other
authors have taken a more robust approach and, for exam-
ple, conducted one or more range-ﬁnding studies prior to their
deﬁnitive studies (e.g. Wong et al., 2013).
The danger of not repeating a study before publishing the
results from a single experiment is well illustrated by the fol-
lowing two  examples, both involving effects of pharmaceuticals
on ﬁsh. Owen et al. (2010) investigated the effects of cloﬁbric
acid, the main metabolite of two representatives of one class of
lipid lowering (hypolipidemic) drugs known as ﬁbrates. In their
ﬁrst experiment, all six concentrations (0.1 g/L to 10 mg/L) of
cloﬁbric acid reduced the growth rate of the ﬁsh, which was
an unexpected result. However, a second experiment, which
was  more powerful in many respects (many more ﬁsh per
concentration, replication of each concentration, etc.), failed
to reproduce the results of the ﬁrst experiment. The authors
(Owen et al., 2010) concluded that the second experiment is
more likely to have provided the ‘right’ (i.e. reproducible) result.
The second example involves diclofenac, a non-steroidal anti-
inﬂammatory drug (NSAID). A number of individual studies
suggested that relatively low g/L concentrations of diclofenac
had major adverse effects on ﬁsh (Schwaiger et al., 2004;
Triebskorn et al., 2004; Hoeger et al., 2005; Mehinto et al., 2010),
but these results were not reproduced in a series of very robust
studies (Memmert et al., 2013). Examples such as these should
caution authors not to publish results of single experiments, or
if they do, to be open and honest about any possible limitations
of their studies in their papers.
(c) Non-standard endpoints.
Although ﬁsh behaviour has been used as an endpoint for
quite some time, in studies on stress and anxiety for example,
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it is not especially easy to quantify. Many different aspects of
ﬁsh behaviour in response to exposure to ﬂuoxetine have been
investigated, including the position of the ﬁsh in a tank, their
exploratory behaviour when placed in a new tank, response to
an alarm pheromone, response to a predator, swimming speed
and aggression. Few of these potential effects have been stud-
ied enough to establish the baseline (of non-exposed ﬁsh) or
the degree of variability of the behavioural endpoint between
individual ﬁsh.
In the case of invertebrates, the endpoints selected, although
often understandable because they are thought to be under
the control of serotonin, are rarely, if ever, well studied. This
is partly a consequence of the fact that only a small proportion
of environmental biologists work with invertebrates, and partly
because there are so many different species of invertebrate to
work with.
Using non-standard endpoints brings a number of major
problems. One is that the baseline is not well established: that
is, what is normal when the organism is not exposed to ﬂuoxe-
tine? The inherent variability around the baseline also needs to
be established. Without knowing the baseline, and how much
it varies, it is impossible to conclude whether or not ﬂuoxetine
has had an effect. Another major problem with utilising non-
standard endpoints is that the factors that alter that baseline
are usually unknown. For example, what environmental condi-
tions affect the endpoint of interest, in what direction, and to
what degree?
Often quantifying non-standard endpoints involves the use
of assays that have not been fully validated for the use they are
put to. This introduces yet another uncertainty.
d) Can clinical data help us?
One huge advantage of studying the environmental impacts
of pharmaceuticals, as opposed to any other group of chemicals,
is that a very large amount of data is available on the chemicals,
particularly on their pharmacokinetics and mode of action. A
number of authors have emphasised the importance of using all
available and appropriate clinical data to guide ecotoxicologi-
cal studies (e.g. Kreke and Dietrich, 2008; Winter et al., 2010;
Berninger and Brooks, 2010). Most of this thinking is encapsu-
lated in the read-across hypothesis (Hugget et al., 2003), which
states that the mode-of-action of a drug will ‘read-across’ from
humans to other organisms, leading to similar effects in the
different organisms (e.g. in humans and ﬁsh) and, further, that
these similar effects will occur at similar blood concentrations.
The current level of support for this hypothesis is discussed in
Rand-Weaver et al. (2013). If this hypothesis was applied to
ﬂuoxetine, it would mean that the main effects of ﬂuoxetine on
aquatic organisms would be behavioural ones, and that these
would occur only when the concentration of ﬂuoxetine in the
blood of the aquatic organism, such as a ﬁsh, was similar to
the human therapeutic concentration (which is between 50 and
300 g/L). Unfortunately, to date nobody has reported plasma
concentrations of ﬂuoxetine in ﬁsh exposed to the drug. There
seems to be an assumption, as discussed above, that effects of
ﬂuoxetine on aquatic organisms will be mode-of-action related.
If that proves to be correct, then one might expect concentra-
tions of ﬂuoxetine in water would need to be in the same range
(tens of hundreds of g’s/L) before effects occur, because the
drug does not bioconcentrate to any signiﬁcant extent, as a con-
sequence of ﬂuoxetine not being particularly hydrophobic, with
a Log D at pH 7.4 of between 1.5 and 2 (Nakamura et al., 2008).
Such reasoning would support the results of the many studies
showing behavioural effects of ﬂuoxetine when water concen-
trations are in the tens or hundreds of gs/L, but question those
reporting behavioural effects at much lower concentrations of
ﬂuoxetine (see earlier discussion).cology 151 (2014) 57–60 59
Knowledge of the serotonin transporter (SERT), the main tar-
get for SSRI anti-depressants, of the zebraﬁsh is very relevant
in this regard (Tatsumi et al., 1997). The anti-depressant ﬂu-
oxetine has a similar afﬁnity for the zebraﬁsh SERT as it does
for the human SERT (Wang et al., 2006). This would suggest
that plasma concentrations of SSRIs such as ﬂuoxetine needed
to cause effects will be similar in ﬁsh and patients (humans)
taking these drugs; that is, upwards of 50 g/L.
The lack of a vertebrate-like blood system in more ‘simple’
aquatic organisms makes the application of the read-across
hypothesis to these organisms more problematic. However, it
has been argued that the reported effects of very low (ng/L) con-
centrations of ﬂuoxetine on a number of species of invertebrates
are very difﬁcult to reconcile with the read-across hypothesis
(Sumpter and Margiotta-Casaluci, 2013). A water concentration
of 0.3 ng/L (Franzellitti et al., 2013) seems unlikely to produce
a concentration of ﬂuoxetine in the nerve synapses of mussels
that is as high as that in the nerve synapses of people taking
the drug to treat their depression; as stated above, it requires
a plasma concentration of between 50 and 300 g/L to pro-
duce serotonin uptake inhibition in these people. Measuring
the internal (perhaps whole body) concentrations of ﬂuoxetine
in the species of invertebrates that seems exquisitely sensitive
to ﬂuoxetine would provide very useful information.
If the target for ﬂuoxetine, the SERT, had a greater afﬁnity
for ﬂuoxetine in some, or all, invertebrates than the vertebrate
SERT does, then lower concentrations of the drug would likely
be required to cause effects. Such a situation could explain why
some invertebrates appear more sensitive to ﬂuoxetine than
vertebrates do. However, this remains only a theoretical possi-
bility until the afﬁnity of the SERT in a range of invertebrates
is established; Sumpter and Margiotta-Casaluci (2013) have
suggested that researchers working with species apparently
extremely sensitive to ﬂuoxetine should conduct the appropri-
ate work.
Other explanations for the apparent much greater sensitivity
of at least some invertebrates to ﬂuoxetine are also possible. For
example, exposure during development may affect the number
and/or afﬁnity of SERT, which in turn could affect the sensitiv-
ity of an organism to ﬂuoxetine. This remains no more than a
theoretical possibility until the idea is tested experimentally.
As stated above, if authors are to claim that their particular
test animal is exquisitely sensitive to ﬂuoxetine, we  consider
it incumbent on them to offer an explanation for the increased
sensitivity, preferably one that they have made an effort to
address experimentally.
(e) What can be concluded?
The answer to this question at the present time must be
“not a great deal”. The apparent variability in the sensitivity
of different aquatic species to ﬂuoxetine prevents any consen-
sus being reached. Does it require concentrations of ﬂuoxetine
in the g/L range to cause effects, or can ng/L, or even sub-ng/L,
concentrations cause effects to at least some species? From
an environmental standpoint, the answer to this question is
extremely important. If the former answer is correct, then envi-
ronmental concentrations of ﬂuoxetine probably do not pose
a threat to aquatic wildlife, but if the latter answer is correct,
then they do. It will probably take many years, and a lot more
research, before a consensus is reached, if it ever is.
Despite what is said above, there is a consensus that ﬂuoxe-
tine affects a wide range of aquatic organisms, both vertebrate
and invertebrate. This is perhaps not surprising, because sero-
tonin seems to be a ubiquitous neurotransmitter, and therefore
serotonin transporters (the target for ﬂuoxetine) are likely to
be equally ubiquitous. Thus effects are to be expected; the only
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elicit those effects. The best situation would be not to have
ﬂuoxetine in the environment; then no effects would occur
however sensitive some organisms were.
We have concentrated on ﬂuoxetine because it is the most
studied anti-depressant from an ecotoxicological perspec-
tive. However, a number of other anti-depressants are in
widespread use clinically, and as a consequence are present
in the aquatic environment. Our conclusions probably apply to
anti-depressants in general.
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